STRS Ohio’s Theravance Biopharma TBPH Stock Holding History

STRS Ohio’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$660K	Sell	38,800 -4,900	-11%	-$81.1K	﹤0.01%	1007
2026 Q1	$709K	Buy	43,700 +7,400	+20%	+$131K	﹤0.01%	838
2025 Q4	$679K	Sell	36,300 -7,800	-18%	-$129K	﹤0.01%	855
2025 Q3	$644K	Buy	+44,100	New	+$557K	﹤0.01%	886
2023 Q3	–	Sell	-32,900	Closed	-$340K	–	2044
2023 Q2	$340K	Buy	32,900 +16,600	+102%	+$183K	﹤0.01%	1434
2023 Q1	$176K	Hold	16,300	–	–	﹤0.01%	1621
2022 Q4	$182K	Buy	+16,300	New	+$171K	﹤0.01%	1613
2016 Q4	–	Sell	-3,700	Closed	-$134K	–	1991
2016 Q3	$134K	Buy	+3,700	New	+$103K	﹤0.01%	1621
2014 Q4	–	Sell	-2,950	Closed	-$68K	–	1801
2014 Q3	$68K	Buy	+2,950	New	+$85.6K	﹤0.01%	1612

Other funds holding TBPH

MAP

Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

ICM

Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

STRS Ohio's TBPH Position: Q2 2026 in Review

STRS Ohio reduced its Theravance Biopharma (TBPH) stake by 11% in Q2 2026, selling an estimated $81.1K and leaving 38,800 shares worth $660K. The position accounts for ﹤0.01% of the portfolio, ranked #1007.

STRS Ohio first reported a position in TBPH in Q3 2014 and has held it in 9 quarters since. The position peaked at $709K in Q1 2026. 181 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

STRS Ohio held 38,800 shares of Theravance Biopharma worth $660K as of Q2 2026.
STRS Ohio sold 4,900 Theravance Biopharma shares in Q2 2026, an estimated $81.1K.
Theravance Biopharma made up ﹤0.01% of STRS Ohio's portfolio in Q2 2026, its #1007 holding.
STRS Ohio first reported a position in Theravance Biopharma in Q3 2014 and has held it in 9 quarters since.
STRS Ohio's Theravance Biopharma position peaked at $709K in Q1 2026.
181 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on STRS Ohio's 13F filing for Q2 2026, filed 30 Jul 2026.